

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

These amendments introduce no new matter and support for the amendment is replete throughout the specification and claims as originally filed. These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter, or agreement with any objection or rejection of record.

Listing of Claims:

Claim 1. (Currently amended) A single chain antibody that specifically binds to a c-erbB2 receptor, wherein said antibody specifically binds to an epitope of said receptor, which epitope binds to ~~bound by~~ F5 (SEQ ID NO:1) or C1 (SEQ ID NO:2), and further wherein said antibody is an internalizing antibody.

Claim 2. (Cancelled)

Claim 3. (Currently amended) The antibody of claim 1, wherein said antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 1 having conservative substitutions in one or more framework regions, and SEQ ID NO: 2 having conservative substitutions in one or more framework regions.

Claim 4 (Currently amended): The antibody of claim 1, wherein said antibody shares at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 as determined using a BLAST algorithm using default parameters, and wherein said antibody has a binding affinity for c-erbB2 on cells of at least 10 mM.

Claim 5 (Currently amended): The antibody of claim 1, wherein the amino acid sequence of said antibody differs from the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 by no more than 30 residues, and wherein residues that differ comprise framework residues.

Claim 6 (Currently amended): The antibody of claim 1, wherein said antibody comprises at least three complementarity determining regions (CDRs), wherein at least one of the three CDRs comprises a complementarity determining region (CDR) of SEQ ID NO: 1.

Claim 7 (Currently amended): The antibody of claim 1, wherein said antibody comprises at least three complementarity determining regions (CDRs), wherein at least one of the three CDRs comprises a complementarity determining region (CDR) of SEQ ID NO: 2.

Claim 8 (Cancelled)

Claim 9 (Cancelled)

Claim 10 (Cancelled)

Claim 11 (Cancelled)

Claim 12 (Currently amended): The antibody of claim 11, wherein said antibody comprises at least three complementarity determining regions (CDRs), wherein the three CDRs comprises three complementarity determining regions of the amino acid sequence of SEQ ID NO: 1.

Claim 13 (Currently amended): The antibody of claim 11, wherein said antibody comprises at least three complementarity determining regions (CDRs), wherein the three CDRs comprises three complementarity determining regions of the amino acid sequence of SEQ ID NO: 2.

Claim 14 (Previously presented): The antibody of claim 1, wherein said antibody comprises the amino acid sequence of SEQ ID NO: 1.

Claim 15 (Previously presented): The antibody of claim 1, wherein said antibody comprises the amino acid sequence of SEQ ID NO: 2.

Claims 16-33 (Canceled).

Claim 34 (Currently amended): A chimeric molecule that specifically binds a cell bearing a c-erbB-2, said chimeric molecule comprising an effector molecule attached to an antibody of ~~claims claim 1 or 16.~~

Claim 35 (Original): The chimeric molecule of claim 34, wherein said effector is selected from the group consisting of a cytotoxin, a label, a radionuclide, a drug, a liposome, a ligand, and an antibody.

Claim 36 (Original): The chimeric molecule of claim 34, wherein said chimeric molecule is a fusion protein.

Claim 37 (Original): The chimeric molecule of claim 34, wherein said cell is a cancer cell.

Claim 38 (Original): The chimeric molecule of claim 37, wherein said cancer cell is a breast cancer cell.

Claim 39 (Currently amended): The chimeric molecule of claim 34, wherein said antibody shares at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 as determined by a BLAST algorithm using default parameters, and wherein said antibody has a binding affinity for c-erbB2 of at least 10 mM.

Claim 40 (Currently amended): The chimeric molecule of claim 34, wherein the amino acid sequence of said antibody differs from the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 by no more than 30 residues, and wherein the at least 30 residues comprise framework residues.

Claim 41 (Currently amended): The chimeric molecule of claim 34, wherein said antibody comprises ~~a complementarity determining region (CDR) of SEQ ID NO: 1~~ the antibody of claim 6.

Claim 42 (Currently amended): The chimeric molecule of claim 34, wherein said antibody comprises ~~a complementarity determining region (CDR) of SEQ ID NO: 2~~ the antibody of claim 7.

Appl. No. 09/250,056
Amdt. Dated April 30, 2004
Reply to Office action of December 31, 2003

Claim 43 (Previously presented): The chimeric molecule of claim 34, wherein said antibody comprises the amino acid sequence of SEQ ID NO: 1.

Claim 44 (Previously presented): The chimeric molecule of claim 34, wherein said antibody comprises the amino acid sequence of SEQ ID NO: 2.

Claim 53 (Currently amended): A composition comprising a pharmacological excipient and the antibody of ~~claims claim 1 or 16~~.

Claim 54 (Original): A composition comprising a pharmacological excipient and the chimeric molecule of claim 34.